Genetic Technologies

Genetic Technologies Limited is a molecular diagnostics company focused on providing predictive testing and assessment tools to enhance women's health management in Australia and the United States. Its primary product, BREVAGenplus, is a clinically validated risk assessment test for non-hereditary breast cancer, which is marketed to healthcare professionals, including breast health care providers and obstetricians/gynecologists. The company is also developing additional cancer risk assessment tests under the GeneType brand for colorectal and breast cancer. In addition to its primary offerings, Genetic Technologies provides a range of genetic testing services, including medical, forensic, animal, and plant testing. The company collaborates with several esteemed institutions, such as the University of Melbourne and Memorial Sloan Kettering, to further its research and development efforts. Founded in 1989 and headquartered in Fitzroy, Australia, Genetic Technologies aims to establish a strong presence in the global market for cancer management tests.